64 results
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
and reimbursement of certain out-of-pocket expenses. As additional compensation we issued to WallachBeth Capital LLC a warrant (the “Placement Agent
424B3
BIAF
BioAffinity Technologies Inc
22 May 24
Prospectus supplement
4:00pm
for the offering and received a cash fee of 9.0% of the aggregate gross proceeds paid to us for the securities sold in the transactions and reimbursement
8-K
EX-99.1
BIAF
BioAffinity Technologies Inc
15 May 24
Results of Operations and Financial Condition
6:07pm
reimbursement for CyPath® Lung became effective on January 1, 2024.
More than 547% annualized growth rate for CyPath® Lung orders in first four months
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
result in significant liability.
Our ability to obtain adequate reimbursement from third-party payors may impact our revenues.
Our employees, consultants … and third-party medical insurance and adequate reimbursement for our diagnostic tests or therapeutic products;
any restrictions on the use of our
POS AM
6l8qv
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-1.1
64iiu4tf ax4ot1o
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
h0f0yau rtku4gypfc
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
ku2s4hfe1ax5fbn7
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
tg7a44djr2t2l
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
pxwk5 czfkjj
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-99.1
9nff wq9p2983
5 Mar 24
Increasing physician interest, newly approved reimbursement code driving growth
5:26pm
8-K
EX-99.1
20xju2lr
30 Nov 23
Regulation FD Disclosure
9:20am
8-K
ctsjf7wb05mmi7pp
30 Nov 23
Regulation FD Disclosure
9:20am
424B5
cdh5eh j4pvyzxcvfe
28 Nov 23
Prospectus supplement for primary offering
4:00pm